| Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015 | 7885 | 2015 |
| Nivolumab plus ipilimumab in advanced melanoma JD Wolchok, H Kluger, MK Callahan, MA Postow, NA Rizvi, AM Lesokhin, ... New England Journal of Medicine 369 (2), 122-133, 2013 | 4984 | 2013 |
| Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET H Peinado, M Alečković, S Lavotshkin, I Matei, B Costa-Silva, ... Nature medicine 18 (6), 883-891, 2012 | 3860 | 2012 |
| Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017 | 3535 | 2017 |
| Immune checkpoint blockade in cancer therapy MA Postow, MK Callahan, JD Wolchok Journal of clinical oncology 33 (17), 1974, 2015 | 2896 | 2015 |
| Immunologic correlates of the abscopal effect in a patient with melanoma MA Postow, MK Callahan, CA Barker, Y Yamada, J Yuan, S Kitano, Z Mu, ... New England Journal of Medicine 366 (10), 925-931, 2012 | 2148 | 2012 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 1955 | 2017 |
| Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at … TZ Horvat, NG Adel, TO Dang, P Momtaz, MA Postow, MK Callahan, ... Journal of Clinical Oncology 33 (28), 3193, 2015 | 1084 | 2015 |
| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709, 2017 | 1054 | 2017 |
| Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ... Cancer cell 33 (5), 843-852. e4, 2018 | 928 | 2018 |
| Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis K Dubin, MK Callahan, B Ren, R Khanin, A Viale, L Ling, D No, ... Nature communications 7 (1), 10391, 2016 | 899 | 2016 |
| Immune-related adverse events of checkpoint inhibitors M Ramos-Casals, JR Brahmer, MK Callahan, A Flores-Chávez, N Keegan, ... Nature reviews Disease primers 6 (1), 38, 2020 | 864 | 2020 |
| Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer MD Hellmann, MK Callahan, MM Awad, E Calvo, PA Ascierto, A Atmaca, ... Cancer cell 33 (5), 853-861. e4, 2018 | 808 | 2018 |
| Hepatotoxicity with combination of vemurafenib and ipilimumab A Ribas, FS Hodi, M Callahan, C Konto, J Wolchok New England Journal of Medicine 368 (14), 1365-1366, 2013 | 798 | 2013 |
| Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ... The lancet oncology 17 (11), 1590-1598, 2016 | 727 | 2016 |
| Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody S Iwama, A De Remigis, MK Callahan, SF Slovin, JD Wolchok, ... Science translational medicine 6 (230), 230ra45-230ra45, 2014 | 667 | 2014 |
| Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas P Lito, CA Pratilas, EW Joseph, M Tadi, E Halilovic, M Zubrowski, ... Cancer cell 22 (5), 668-682, 2012 | 594 | 2012 |
| Immune modulation in cancer with antibodies DB Page, MA Postow, MK Callahan, JP Allison, JD Wolchok Annual review of medicine 65, 185-202, 2014 | 557 | 2014 |
| Targeting T cell co-receptors for cancer therapy MK Callahan, MA Postow, JD Wolchok Immunity 44 (5), 1069-1078, 2016 | 503 | 2016 |
| Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution M Ryder, M Callahan, MA Postow, J Wolchok, JA Fagin Endocrine-related cancer 21 (2), 371-381, 2014 | 472 | 2014 |
